Annick Moens, Karen van Hoeve, Evelien Humblet, Jean-François Rahier, Peter Bossuyt, Sophie Dewit, Denis Franchimont, Elisabeth Macken, Jochen Nijs, Annelies Posen, Beatrijs Strubbe, Anneleen Van Hootegem, Wouter Van Moerkercke, Séverine Vermeire, Marc Ferrante
Background and Aims: Vedolizumab is an IgG1 anti-α4β7 integrin antibody approved for the treatment of inflammatory bowel diseases [IBD], but without clear safety data during conception, pregnancy and nursing. Animal studies showed that mucosal vascular addressin cell adhesion molecule 1 [MAdCAM-1] is expressed by maternal vessels in the placenta and recruits α4β7-expressing cells that are considered important for maternal/fetal tolerance. Blocking this interaction by vedolizumab might affect this process...
January 1, 2019: Journal of Crohn's & Colitis